128 results about "Hemorrhagic shock" patented technology

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

Methods and apparatus (20 ) process noninvasively measured electrical bio-impedence values and perform a technique that indicates whether there exists a change from a homeostatic fluid condition, preferably with respect to blood loss, in mammalian tissue. Analyses can be performed to determine a presence or a change in volume of fluid in an anatomical space of a mammal. A preferred implementation of such technique is embodied in an instrument that carries out a method that may predict an onset of a hemorrhagic shock condition.

The present invention relates to compositions and methods for providing mitochondria-selective targeting agents covalently linked to desired cargo such as radical scavenging agents. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels. In further preferred embodiments, the composition for scavenging radicals in a mitochondrial membrane includes a radical scavenging agent and a membrane active compound having a high affinity with said mitochondrial membrane and associated methods. In another embodiment, the cargo transported by mitochondrial-selective targeting agents may include an inhibitor of nitrous oxide system (NOS) enzyme activity.

Bleeding from blood vessels located in difficult-to-compress regions of the body (especially the abdomen, pelvic or groin region) is controlled by the use of a portable, small-footprint belt-like device that contains multiple inflatable bladders. The inflatable bladders are selectively positioned and inflated over exsanguinating blood vessels, thereby exerting pressure to stop the bleeding. The device may also be used to provide perfusion support in low flow disease states such as hemorrhagic shock and cardiac arrest.

Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria dysfunction and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels.

A method of treating hemorrhagic shock with a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.8 to about 5.5, a surfactant and a polyol.

The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.

Systems and methods for prediction and detection of circulatory shock using estimates or measurements of arterial blood pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, cardiac ejection fraction, cardiac contractility and ventricular end-diastolic volume are provided. These estimates and measurements are used to determine a type of circulatory shock. In some embodiments, the type of circulatory shock is determined to be one of septic shock, hypovolemic shock, anaphylactic shock, hemorrhagic shock, and cardiogenic shock.

The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.

The invention discloses application of penehyclidine hydrochloride in preparation of a medicine for treating a hemorrhagic shock disease. Hemorrhagic shock has a pathological change that the central venous pressure, the peripheral mean arterial pressure and the cardiac output are all obviously reduced and the middle-light microcirculatory disturbance appears, the medicine for treating the hemorrhagic shock disease can be liquid and can also be solid, and the mass percent concentration of the penehyclidine hydrochloride in the medicine is between 0.01 and 2 percent. The application effect is proved through the influence of a penehyclidine hydrochloride water solution on a canine hemorrhagic shock model.

A real-time decision-support system predicts hemorrhagic shock of a patient by analysis of electrocardiogram (ECG) signals and transcranial Doppler (TCD) signals from the patient. These signals are subject to signal decomposition using Discrete Wavelet Transform (DWT) to sets of wavelet coefficients and selecting significant signal features. Machine learning is applied to the significant features to evaluate and classify hypovolemia severity based on the input ECG and TCD signals from the patient. The classification of blood loss severity is displayed in real-time. An extension of the decision-support system integrates Arterial Blood Pressure (ABP) signals and thoracic electrical bio-impedance (DZT) signals with the ECG and TCD signals from the patient to evaluate severity of hypovolemia.

The present invention relates to process for controlling water and electrolyte balance and acid-base equilibrium, and particularly to process for controlling water and electrolyte balance and acid-base equilibrium supervening metabolic acidosis due to burn injury, hemorrhagic shock, multiple organ failure, systemic inflammatory response syndrome (SIRS), and so on. By administering the preparation containing sodium bicarbonate as an alkalizing agent of the present invention, the acidosis correction effect is exhibited immediately after the start of the infusion and disappeared quickly by demedication. And therefore, the preparation of the present invention can be administered safely without inducing metabolic alkalosis during infusion and alkalosis after the infusion. The preparation of the present invention also has no problem with hypernatremia. The controlling water and electrolyte balance and acid-base equilibrium, and particularly to process for controlling water and electrolyte balance can be done by administering the preparation containing bicarbonate at a rate of 2 to 60 mL/kg/hour.

The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.

The present invention concerns the use of polychalcogenide compositions on cells, tissue, organs, and organisms to enhance their survivability. It includes compositions, compounds, methods, articles of manufacture and apparatuses for enhancing survivability and for protecting them from or treating them for injury or damage. In specific embodiments, there are also therapeutic methods and apparatuses for hypoxic/ischemic injury, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the polychalcogenide compositions described.

The invention provides a traumatic hemorrhagic shock injury time sequence prediction method, which comprises the following steps of: extracting traumatic hemorrhagic shock injury data from a database, and performing data processing on the traumatic hemorrhagic shock injury data, including processing a data abnormal value, and performing linear vacancy filling and clustering vacancy filling on the data; designing a stepped index for the processed data; and constructing a prediction model by applying the index stepped result and different types of classifiers, and predicting a result after a preset duration through the prediction model. According to the invention, time series data with serious missing can be processed, time series rather than cross section prediction is carried out, and the obtained prediction result is more accurate; a prediction time window is introduced, a prediction index stepped concept is provided, and real-time dynamic prediction and early warning based on a time sequence can be carried out on traumatic hemorrhagic shock by using indexes capable of being monitored in real time.

The invention relates to a disposable hemostatic dressing wound leading-in first-aid hemostasis instrument, and belongs to the field of medical apparatuses and instruments. The instrument comprises a hemostatic material loading component and a pushing component. The hemostatic material loading component is used for storing compression-pill-shaped or flake chitosan hemostatic materials, and the front end is packaged through waterproof and breathable silica gel materials; and the pushing component is used for rapidly pressing the hemostatic materials into a wound. The disposable hemostatic dressing wound leading-in first-aid hemostasis instrument is particularly rapid and reliable in hemostatic effect on firearm wounds, penetration wounds and deep pricking wounds which are smaller in body surface penetration wound, large in internal wound and large in bleeding amount in battlefield rescuing. The disposable hemostatic dressing wound leading-in first-aid hemostasis instrument has the advantages that the efficient hemostatic materials are led into the deep wounds; as for tissue deep bleeding parts where bleeding stopping through a tourniquet or pressing is not suitable, the device can achieve the effects of accurate positioning, rapid bleeding stopping and hemorrhagic shock and dead preventing. When traumas accidentally occur, self rescuing or other rescuing can be carried out, and the valuable rescuing time can be won. The device has the advantages of being efficient in bleeding stopping, easy and convenient to operate, low in cost, convenient to carry, long in storage time and convenient to use.